Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Abstract: Herein disclosed is a surface-mounted NFC antenna, having a small size and good performance, comprising a magnetic core, a first dielectric layer, a first coil and a second coil. The first coil is wound on the outer surface of the magnetic core. One side of the first dielectric layer, away from the magnetic core, is the first surface. The second coil is disposed on the first surface. The tail end of the first coil is electrically connected with the head end of the second coil. In the NFC antenna, the second coil is disposed on the dielectric layer to separate the first coil from the second coil, thereby preventing the magnetic field generated by the first coil from weakening the magnetic field generated by the second coil, so the magnetic field generated by the second coil is relatively larger.

Abstract: A semi-manufactured power semiconductor module includes a substrate for bonding at least one power semiconductor chip; a first leadframe bonded to the substrate and providing power terminals; and a second leadframe bonded to the substrate and providing auxiliary terminals; wherein the first leadframe and/or the second leadframe include an interlocking element adapted for aligning the first leadframe and the second leadframe with respect to each other and/or with respect to a mold for molding an encapsulation around the substrate, the first leadframe and the second leadframe.

Abstract: Herein disclosed is a surface-mounted NFC antenna, having a small size and good performance, comprising a magnetic core, a first dielectric layer, a first coil and a second coil. The first coil is wound on the outer surface of the magnetic core. One side of the first dielectric layer, away from the magnetic core, is the first surface. The second coil is disposed on the first surface. The tail end of the first coil is electrically connected with the head end of the second coil. In the NFC antenna, the second coil is disposed on the dielectric layer to separate the first coil from the second coil, thereby preventing the magnetic field generated by the first coil from weakening the magnetic field generated by the second coil, so the magnetic field generated by the second coil is relatively larger.

Abstract: Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1, and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical expositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.

Abstract: A mounting member for a vehicle, the mounting member including a mounting member body having a longitudinal axis, at least one static opening extending through the body transverse to the longitudinal axis, and at least one blind listener bushing, each blind fastener bushing having a bushing body and a blind fastener receptacle extending axially through the bushing body. The bushing body has a bushing cross-sectional shape that interlocks and couples with a static opening cross-sectional shape of a respective one of the at least one static opening so that rotation of the at least one blind fastener bushing is constrained relative to the mounting member body and the static opening cross-sectional shape is maintained upon application of a blind fastener installation torque or blind fastener removal torque being applied to the blind fastener receptacle by a respective blind fastener.

Abstract: Systems, methods, and apparatus for a modular replaceable slip joint intercostal are disclosed. In one or more embodiments, an intercostal apparatus for a vehicle comprises a body, where the body is greater in length than in width. In at least one embodiment, the intercostal apparatus further comprises at least one slip joint opening located proximate an end of the body to slidably receive a bushing and a fastener, where the bushing rigidly attaches to a top surface of a seat track by the fastener.

Abstract: Disclosed herein are inventive polypeptides (e.g., comprising a thermal sensitive ion channel or variant thereof and a domain 5 of kininogen 1 or variant or fragment thereof) and nucleic acid molecules encoding inventive polypeptides. Also disclosed are methods for modulating a cell comprising administering certain compositions (e.g., pharmaceutical compositions of the nucleic acid molecule) and applying a static magnetic field or an electromagnetic field. Methods for treating diseases or disorders in an animal (e.g., a human) comprising administering certain compositions (e.g., pharmaceutical compositions of the nucleic acid molecule) and applying a static magnetic field or an electromagnetic field, are further disclosed.

Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: Systems and methods for imaging and quantifying tissue magnetism with magnetic resonance imaging (MRI) are disclosed. According to an aspect, a method for MRI includes using an MRI system to acquire multiple image echoes of an object. The method also includes combining the image echoes. Further, the method includes generating an image of the object based on the combined image echoes for depicting a characteristic of the object.

Abstract: Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1, and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical expositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.

Abstract: The present disclosure provides a method and system for quantifying and making images of tissue anisotropy property based on magnetic resonance imaging (MRI). The systems and methods provided herein utilize orientation distribution of magnetic susceptibility to characterize magnetic susceptibility anisotropy (MSA) inside biological tissues. This MSA may be intrinsic property of the tissue or may be induced by the presence of external agents. In certain embodiments, the MSA is displayed as an orientation distribution function of susceptibility and/or may be described by mathematical quantities such as tensors (e.g., symmetric or asymmetric second order or higher order tensors) and spherical harmonics. In other embodiments, the MSA is characterized using a second order tensor named apparent susceptibility tensor (AST).

Abstract: Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical compositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.

Abstract: The present disclosure describes a power electronics module comprising a lead frame in which a chip of a first semiconductor device is embedded, a first PCB mounted on top of the lead frame and the chip of the first semiconductor device, and a support frame mounted on top of the PCB, the support frame comprising a cavity in which the chip of a second semiconductor device is embedded, wherein the chips of the first semiconductor device and the second semiconductor device are positioned on top of each other, and the first PCB comprises a first electrically conducting path between the chips of the first semiconductor device and the second semiconductor device.

Abstract: Systems and methods for imaging and quantifying tissue magnetism with magnetic resonance imaging (MRI) are disclosed. According to an aspect, a method for MRI includes using an MRI system to acquire multiple image echoes of an object. The method also includes combining the image echoes. Further, the method includes generating an image of the object based on the combined image echoes for depicting a characteristic of the object.

Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: Systems, methods, and apparatus for a modular replaceable slip joint intercostal are disclosed. In one or more embodiments, an intercostal apparatus for a vehicle comprises a body, where the body is greater in length than in width. In at least one embodiment, the intercostal apparatus further comprises at least one slip joint opening located proximate an end of the body to slidably receive a bushing and a fastener, where the bushing rigidly attaches to a top surface of a seat track by the fastener.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.